Peripheral analgesia: Hitting pain where it hurts

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 4, 2011, Pages 459-467

  McDougall, Jason J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Animal model of disease; Nociception; Novel target; Pain; Peripheral analgesia

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 (1,3 DIMETHYL 2,6 DIOXO 1,2,3,6 TETRAHYDRO 7H PURIN 7YL) N (4 ISOPROPYLPHENYL)ACETAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 (4 CHLOROPHYNYL) 3 METHYLBUTYL 3 EN 2 OXIME; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; 5 BENZYLOXYTRYPTAMINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANALGESIC AGENT; AP 18; CANNABINOID RECEPTOR; CAPSAZEPINE; DEXANABINOL; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; ENMD 1068; HC 030031; HC 067047; L 759633; L 759656; OPIATE RECEPTOR; PROTEINASE ACTIVATED RECEPTOR; RN 1734; RWJ 58259; SCH 205831; SCH 5303048; SRI 44528; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; COLD SENSATION; HUMAN; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PERIPHERAL ANALGESIA; PRIORITY JOURNAL; REVIEW; SENSITIZATION; TEMPERATURE SENSITIVITY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; HUMANS; PAIN; PERIPHERAL NERVES; RECEPTORS, G-PROTEIN-COUPLED; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

ANIMALIA;

EID: 79151481510     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.12.011     Document Type: Review

References (135)

1. Turk D.C., Okifuji A. Pain terms and taxonomies of pain. Bonica's Management of Pain 2009, 14-23. Lippincott Williams & Wilkins, Philadelphia, PA, USA. S.M. Fishman, J.C. Ballantyne, J.P. Rathmell (Eds.).
2. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
3. Karimian S.M., McDougall J.J., Ferrell W.R. Neuropeptidergic and autonomic control of the vasculature of the rat knee joint revealed by laser Doppler perfusion imaging. Exp. Physiol. 1995, 80:341-348.
4. Varga A., Nemeth J., Szabo A., McDougall J.J., Zhang C., Elekes K., Pinter E., Szolcsanyi J., Helyes Z. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci. Lett. 2005, 385:137-142.
5. Barton N.J., McQueen D.S., Thomson D., Gauldie S.D., Wilson A.W., Salter D.M., Chessell I.P. Attenuation of experimental arthritis in TRPV1R knockout mice. Exp. Mol. Pathol. 2006, 81:166-170.
6. Szabo A., Helyes Z., Sandor K., Bite A., Pinter E., Nemeth J., Banvolgyi A., Bolcskei K., Elekes K., Szolcsanyi J. Role of transient receptor potential vanilloid 1 receptors in adjuvant-induced chronic arthritis: in vivo study using gene-deficient mice. J. Pharmacol. Exp. Ther. 2005, 314:111-119.
7. Keeble J., Russell F., Curtis B., Starr A., Pinter E., Brain S.D. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum. 2005, 52:3248-3256.
8. Honore P., Wismer C.T., Mikusa J., Zhu C.Z., Zhong C., Gauvin D.M., Gomtsyan A., El Kouhen R., Lee C.H., Marsh K., Sullivan J.P., Faltynek C.R., Jarvis M.F. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther. 2005, 314:410-421.
9. Akbar A., Yiangou Y., Facer P., Walters J.R., Anand P., Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008, 57:923-929.
10. Hughes P.A., Brierley S.M., Martin C.M., Liebregts T., Persson J., Adam B., Holtmann G., Blackshaw L.A. TRPV1-expressing sensory fibres and IBS: links with immune function. Gut 2009, 58:465-466.
11. Gavva N.R., Bannon A.W., Surapaneni S., Hovland D.N., Lehto S.G., Gore A., Juan T., Deng H., Han B., Klionsky L., Kuang R., Le A., Tamir R., Wang J., Youngblood B., Zhu D., Norman M.H., Magal E., Treanor J.J., Louis J.C. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci. 2007, 27:3366-3374.
12. Swanson D.M., Dubin A.E., Shah C., Nasser N., Chang L., Dax S.L., Jetter M., Breitenbucher J.G., Liu C., Mazur C., Lord B., Gonzales L., Hoey K., Rizzolio M., Bogenstaetter M., Codd E.E., Lee D.H., Zhang S.P., Chaplan S.R., Carruthers N.I. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 2005, 48:1857-1872.
13. Steiner A.A., Turek V.F., Almeida M.C., Burmeister J.J., Oliveira D.L., Roberts J.L., Bannon A.W., Norman M.H., Louis J.C., Treanor J.J., Gavva N.R., Romanovsky A.A. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci. 2007, 27:7459-7468.
14. Tamayo N., Liao H., Stec M.M., Wang X., Chakrabarti P., Retz D., Doherty E.M., Surapaneni S., Tamir R., Bannon A.W., Gavva N.R., Norman M.H. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. J. Med. Chem. 2008, 51:2744-2757.
15. Lehto S.G., Tamir R., Deng H., Klionsky L., Kuang R., Le A., Lee D., Louis J.C., Magal E., Manning B.H., Rubino J., Surapaneni S., Tamayo N., Wang T., Wang J., Wang W., Youngblood B., Zhang M., Zhu D., Norman M.H., Gavva N.R. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2, 3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther. 2008, 326:218-229.
16. Suzuki M., Watanabe Y., Oyama Y., Mizuno A., Kusano E., Hirao A., Ookawara S. Localization of mechanosensitive channel TRPV4 in mouse skin. Neurosci. Lett. 2003, 353:189-192.
17. Mutai H., Heller S. Vertebrate and invertebrate TRPV-like mechanoreceptors. Cell Calcium 2003, 33:471-478.
18. Vriens J., Owsianik G., Fisslthaler B., Suzuki M., Janssens A., Voets T., Morisseau C., Hammock B.D., Fleming I., Busse R., Nilius B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ. Res. 2005, 97:908-915.
19. Watanabe H., Vriens J., Prenen J., Droogmans G., Voets T., Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003, 424:434-438.
20. Liedtke W., Choe Y., Marti-Renom M.A., Bell A.M., Denis C.S., Sali A., Hudspeth A.J., Friedman J.M., Heller S. Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 2000, 103:525-535.
21. Suzuki M., Mizuno A., Kodaira K., Imai M. Impaired pressure sensation in mice lacking TRPV4. J. Biol. Chem. 2003, 278:22664-22668.
22. Brierley S.M., Page A.J., Hughes P.A., Adam B., Liebregts T., Cooper N.J., Holtmann G., Liedtke W., Blackshaw L.A. Selective role for TRPV4 ion channels in visceral sensory pathways. Gastroenterology 2008, 134:2059-2069.
23. Jaquemar D., Schenker T., Trueb B. An ankyrin-like protein with transmembrane domains is specifically lost after oncogenic transformation of human fibroblasts. J. Biol. Chem. 1999, 274:7325-7333.
24. Story G.M., Peier A.M., Reeve A.J., Eid S.R., Mosbacher J., Hricik T.R., Earley T.J., Hergarden A.C., Andersson D.A., Hwang S.W., McIntyre P., Jegla T., Bevan S., Patapoutian A. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003, 112:819-829.
25. Katsura H., Obata K., Mizushima T., Yamanaka H., Kobayashi K., Dai Y., Fukuoka T., Tokunaga A., Sakagami M., Noguchi K. Antisense knock down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp. Neurol. 2006, 200:112-123.
26. Frederick J., Buck M.E., Matson D.J., Cortright D.N. Increased TRPA1, TRPM8, and TRPV2 expression in dorsal root ganglia by nerve injury. Biochem. Biophys. Res. Commun. 2007, 358:1058-1064.
27. Bautista D.M., Jordt S.E., Nikai T., Tsuruda P.R., Read A.J., Poblete J., Yamoah E.N., Basbaum A.I., Julius D. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 2006, 124:1269-1282.
28. Kwan K.Y., Allchorne A.J., Vollrath M.A., Christensen A.P., Zhang D.S., Woolf C.J., Corey D.P. TRPA1 contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 2006, 50:277-289.
29. Klionsky L., Tamir R., Gao B., Wang W., Immke D.C., Nishimura N., Gavva N.R. Species-specific pharmacology of trichloro(sulfanyl)ethyl benzamides as transient receptor potential ankyrin 1 (TRPA1) antagonists. Mol. Pain 2007, 3:39.
30. McNamara C.R., Mandel-Brehm J., Bautista D.M., Siemens J., Deranian K.L., Zhao M., Hayward N.J., Chong J.A., Julius D., Moran M.M., Fanger C.M. TRPA1 mediates formalin-induced pain. Proc. Natl Acad. Sci. USA 2007, 104:13525-13530.
31. Eid S.R., Crown E.D., Moore E.L., Liang H.A., Choong K.C., Dima S., Henze D.A., Kane S.A., Urban M.O. HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain 2008, 4:48.
32. E.S. Fernandes, F.A. Russell, D. Spina, J.J. McDougall, R. Graepel, C. Gentry, A.A. Staniland, J.E. Keeble, M. Malcangio, S. Bevan, S.D. Brain, A distinct role for TRPA1, in addition to TRPV1, in mechanical hypernociception induced by TNFα and in CFA-induced monoarthritis. Arthritis Rheum. (in press), doi:10.1002/art.30150.
33. McKemy D.D., Neuhausser W.M., Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002, 416:52-58.
34. Peier A.M., Moqrich A., Hergarden A.C., Reeve A.J., Andersson D.A., Story G.M., Earley T.J., Dragoni I., McIntyre P., Bevan S., Patapoutian A. A TRP channel that senses cold stimuli and menthol. Cell 2002, 108:705-715.
35. Bautista D.M., Siemens J., Glazer J.M., Tsuruda P.R., Basbaum A.I., Stucky C.L., Jordt S.E., Julius D. The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 2007, 448:204-208.
36. Proudfoot C.J., Garry E.M., Cottrell D.F., Rosie R., Anderson H., Robertson D.C., Fleetwood-Walker S.M., Mitchell R. Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr. Biol. 2006, 16:1591-1605.
37. Xing H., Chen M., Ling J., Tan W., Gu J.G. TRPM8 mechanism of cold allodynia after chronic nerve injury. J. Neurosci. 2007, 27:13680-13690.
38. Dery O., Corvera C.U., Steinhoff M., Bunnett N.W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am. J. Physiol. Cell Physiol. 1998, 274:C1429-C1452.
39. Martin L., Auge C., Boue J., Buresi M.C., Chapman K., Asfaha S., Andrade-Gordon P., Steinhoff M., Cenac N., Dietrich G., Vergnolle N. Thrombin receptor: an endogenous inhibitor of inflammatory pain, activating opioid pathways. Pain 2009, 146:121-129.
40. Asfaha S., Brussee V., Chapman K., Zochodne D.W., Vergnolle N. Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br. J. Pharmacol. 2002, 135:1101-1106.
41. Kawabata A., Kawao N., Kuroda R., Tanaka A., Shimada C. The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. Peptides 2002, 23:1181-1183.
42. Steinhoff M., Vergnolle N., Young S.H., Tognetto M., Amadesi S., Ennes H.S., Trevisani M., Hollenberg M.D., Wallace J.L., Caughey G.H., Mitchell S.E., Williams L.M., Geppetti P., Mayer E.A., Bunnett N.W. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat. Med. 2000, 6:151-158.
43. Helyes Z., Sandor K., Borbely E., Tekus V., Pinter E., Elekes K., Toth D.M., Szolcsanyi J., McDougall J.J. Involvement of transient receptor potential vanilloid 1 receptors in protease-activated receptor-2-induced joint inflammation and nociception. Eur. J. Pain 2010, 14:351-358.
44. Coelho A.M., Vergnolle N., Guiard B., Fioramonti J., Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 2002, 122:1035-1047.
45. Vergnolle N., Hollenberg M.D., Sharkey K.A., Wallace J.L. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 1999, 127:1083-1090.
46. Grant A.D., Cottrell G.S., Amadesi S., Trevisani M., Nicoletti P., Materazzi S., Altier C., Cenac N., Zamponi G.W., Bautista-Cruz F., Lopez C.B., Joseph E.K., Levine J.D., Liedtke W., Vanner S., Vergnolle N., Geppetti P., Bunnett N.W. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J. Physiol. 2007, 578:715-733.
47. D'Andrea M.R., Rogahn C.J., Andrade-Gordon P. Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech. Histochem. 2000, 75:85-90.
48. Martel-Pelletier J., Cloutier J.M., Pelletier J.P. Neutral proteases in human osteoarthritic synovium. Arthritis Rheum. 1986, 29:1112-1121.
49. Nakano S., Ikata T., Kinoshita I., Kanematsu J., Yasuoka S. Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin. Exp. Rheumatol. 1999, 17:161-170.
50. Gecse K., Roka R., Ferrier L., Leveque M., Eutamene H., Cartier C., Ait-Belgnaoui A., Rosztoczy A., Izbeki F., Fioramonti J., Wittmann T., Bueno L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008, 57:591-599.
51. Russell F.A., Veldhoen V.E., Tchitchkan D., McDougall J.J. Proteinase-activated receptor-4 (PAR4) activation leads to sensitization of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism. J. Neurophysiol. 2010, 103:155-163.
52. McDougall J.J., Zhang C., Cellars L., Joubert E., Dixon C.M., Vergnolle N. Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice. Arthritis Rheum. 2009, 60:728-737.
53. D'Andrea M.R., Saban M.R., Nguyen N.B., Andrade-Gordon P., Saban R. Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am. J. Pathol. 2003, 162:907-923.
54. Asfaha S., Cenac N., Houle S., Altier C., Papez M.D., Nguyen C., Steinhoff M., Chapman K., Zamponi G.W., Vergnolle N. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br. J. Pharmacol. 2007, 150:176-185.
55. Auge C., Balz-Hara D., Steinhoff M., Vergnolle N., Cenac N. Protease-activated receptor-4 (PAR 4): a role as inhibitor of visceral pain and hypersensitivity. Neurogastroenterol. Motil. 2009, 21:1189-e1107.
56. Annahazi A., Gecse K., Dabek M., Ait-Belgnaoui A., Rosztoczy A., Roka R., Molnar T., Theodorou V., Wittmann T., Bueno L., Eutamene H. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009, 144:209-217.
57. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
58. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
59. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
60. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4:873-884.
61. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
62. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., Stella N., Makriyannis A., Piomelli D., Davison J.S., Marnett L.J., Di Marzo V., Pittman Q.J., Patel K.D., Sharkey K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
63. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002, 121:173-190.
64. Pertwee R.G. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci. 1999, 65:597-605.
65. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63:569-611.
66. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
67. McDougall J.J. Cannabinoids and pain control in the periphery. Peripheral Receptor Targets for Analgesia 2009, 325-345. John Wiley & Sons Inc., Hoboken, NJ. B.E. Cairns (Ed.).
68. Schuelert N., McDougall J.J. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthritis Rheum. 2008, 58:145-153.
69. Cox M.L., Haller V.L., Welch S.P. The antinociceptive effect of delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur. J. Pharmacol. 2007, 570:50-56.
70. Croci T., Zarini E. Effect of the cannabinoid CB(1) receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br. J. Pharmacol. 2007, 150:559-566.
71. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 1998, 60:183-191.
72. Baker C.L., McDougall J.J. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br. J. Pharmacol. 2004, 142:1361-1367.
73. McDougall J.J., Yu V., Thomson J. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br. J. Pharmacol. 2008, 153:358-366.
74. Hudson L.J., Bevan S., Wotherspoon G., Gentry C., Fox A., Winter J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur. J. Neurosci. 2001, 13:2105-2114.
75. Yiangou Y., Facer P., Dyer N.H., Chan C.L., Knowles C., Williams N.S., Anand P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 2001, 357:1338-1339.
76. Amaya F., Shimosato G., Kawasaki Y., Hashimoto S., Tanaka Y., Ji R.R., Tanaka M. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006, 124:175-183.
77. Cesare P., Dekker L.V., Sardini A., Parker P.J., McNaughton P.A. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999, 23:617-624.
78. Di Marzo V., Blumberg P.M., Szallasi A. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 2002, 12:372-379.
79. Hong S., Wiley J.W. Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J. Biol. Chem. 2005, 280:618-627.
80. Premkumar L.S., Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408:985-990.
81. Noyes R., Brunk S.F., Avery D.A., Canter A.C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 1975, 18:84-89.
82. Michalski C.W., Laukert T., Sauliunaite D., Pacher P., Bergmann F., Agarwal N., Su Y., Giese T., Giese N.A., Batkai S., Friess H., Kuner R. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 2007, 132:1968-1978.
83. Hamamoto D.T., Giridharagopalan S., Simone D.A. Acute and chronic administration of the cannabinoid receptor agonist CP 55, 940 attenuates tumor-evoked hyperalgesia. Eur. J. Pharmacol. 2007, 558:73-87.
84. Kehl L.J., Hamamoto D.T., Wacnik P.W., Croft D.L., Norsted B.D., Wilcox G.L., Simone D.A. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003, 103:175-186.
85. Guerrero A.V., Quang P., Dekker N., Jordan R.C., Schmidt B.L. Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci. Lett. 2008, 433:77-81.
86. Welburn P.J., Starmer G.A., Chesher G.B., Jackson D.M. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 1976, 46:83-85.
87. Sanson M., Bueno L., Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil. 2006, 18:949-956.
88. Scott D.A., Wright C.E., Angus J.A. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004, 109:124-131.
89. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 1997, 221:157-160.
90. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001, 92:91-100.
91. Pol O., Murtra P., Caracuel L., Valverde O., Puig M.M., Maldonado R. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain. Neuropharmacology 2006, 50:123-132.
92. Castane A., Celerier E., Martin M., Ledent C., Parmentier M., Maldonado R., Valverde O. Development and expression of neuropathic pain in CB1 knockout mice. Neuropharmacology 2006, 50:111-122.
93. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007, 10:870-879.
94. Elmes S.J., Jhaveri M.D., Smart D., Kendall D.A., Chapman V. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur. J. Neurosci. 2004, 20:2311-2320.
95. Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Vanderah T.W., Lai J., Porreca F., Makriyannis A., Malan T.P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl Acad. Sci. USA 2003, 100:10529-10533.
96. Valenzano K.J., Tafesse L., Lee G., Harrison J.E., Boulet J.M., Gottshall S.L., Mark L., Pearson M.S., Miller W., Shan S., Rabadi L., Rotshteyn Y., Chaffer S.M., Turchin P.I., Elsemore D.A., Toth M., Koetzner L., Whiteside G.T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005, 48:658-672.
97. Whiteside G.T., Gottshall S.L., Boulet J.M., Chaffer S.M., Harrison J.E., Pearson M.S., Turchin P.I., Mark L., Garrison A.E., Valenzano K.J. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur. J. Pharmacol. 2005, 528:65-72.
98. Pert C.B., Snyder S.H. Opiate receptor: demonstration in nervous tissue. Science 1973, 179:1011-1014.
99. Simon E.J., Hiller J.M., Edelman I. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. Proc. Natl Acad. Sci. USA 1973, 70:1947-1949.
100. Terenius L. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol. Toxicol. (Copenh.) 1973, 33:377-384.
101. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 1976, 197:517-532.
102. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258:577-580.
103. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarquil H., Vassart G., Parmentier M., Costentin J. Isolation and structure of the endogenous agonist of opioid receptor- like ORL1 receptor. Nature 1995, 377:532-535.
104. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein- coupled receptor. Science 1995, 270:792-794.
105. Wuster M., Schulz R., Herz A. Multiple opiate receptors in peripheral tissue preparations. Biochem. Pharmacol. 1981, 30:1883-1887.
106. Ferreira S.H., Nakamura M. Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 1979, 18:191-200.
107. Joris J.L., Dubner R., Hargreaves K.M. Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation?. Anaesth. Analg. 1987, 66:1277-1281.
108. Russell N.J., Schaible H.G., Schmidt R.F. Opiates inhibit the discharges of fine afferent units from inflamed knee joint of the cat. Neurosci. Lett. 1987, 76:107-112.
109. Stein C., Millan M.J., Shippenberg T.S. Peripheral opioid receptors mediating antinociception in inflammation: evidence for mu, delta, and kappa receptors. J. Pharmacol. Exp. Ther. 1989, 248:1269-1275.
110. Takemori A.E., Ho B.Y., Naeseth J.S., Portoghese P.S. Nor-binaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J. Pharmacol. Exp. Ther. 1988, 246:255-258.
111. Kramer T.H., Shook J.E., Kazmierski W., Ayres E.A., Wire W.S., Hruby V.J., Burks T.F. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 1989, 249:544-551.
112. Cotton R., Giles M.G., Miller L., Shaw J.S., Timms D. ICI 174864: a highly selective antagonist for the opioid delta-receptor. Eur. J. Pharmacol. 1984, 97:331-332.
113. Baamonde A., Lastra A., Juarez L., Garcia V., Hidalgo A., Menendez L. Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia. Naunyn Schmiedebergs Arch. Pharmacol. 2005, 372:213-219.
114. McDougall J.J., Larson S.E.M. Nociceptin/orphanin FQ evokes knee joint pain in rats via a mast cell independent mechanism. Neurosci. Lett. 2006, 398:135-138.
115. McDougall J.J., Hanesch U., Pawlak M., Schmidt R.F. Participation of NK1 receptors in nociceptin-induced modulation of rat knee joint mechanosensitivity. Exp. Brain Res. 2001, 137:249-253.
116. McDougall J.J., Pawlak M., Hanesch U., Schmidt R.F. Peripheral modulation of rat knee joint afferent mechanosensitivity by nociceptin/orphanin FQ. Neurosci. Lett. 2000, 288:123-126.
117. Inoue M., Kobayashi M., Kozaki S., Zimmer A., Ueda H. Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. Proc. Natl Acad. Sci. 1998, 95:10949-10953.
118. McDougall J.J., Pawlak M., Hanesch U., Schmidt R.F. Peripheral modulation of rat knee joint afferent mechanosensitivity by nociceptin/orphanin FQ. Neurosci. Lett. 2000, 288:123-126.
119. Agostini S., Eutamene H., Broccardo M., Improta G., Petrella C., Theodorou V., Bueno L. Peripheral anti-nociceptive effect of nociceptin/orphanin FQ in inflammation and stress-induced colonic hyperalgesia in rats. Pain 2009, 141:292-299.
120. Ko M.C., Naughton N.N., Traynor J.R., Song M.S., Woods J.H., Rice K.C., McKnight A.T. Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors. Br. J. Pharmacol. 2002, 135:943-950.
121. Kolesnikov Y.A., Pasternak G.W. Peripheral orphanin FQ/nociceptin analgesia in the mouse. Life Sci. 1999, 64:2021-2028.
122. Ambriz-Tututi M., Rocha-Gonzalez H.I., Castaneda-Corral G., Araiza-Saldana C.I., Caram-Salas N.L., Cruz S.L., Granados-Soto V. Role of opioid receptors in the reduction of formalin-induced secondary allodynia and hyperalgesia in rats. Eur. J. Pharmacol. 2009, 619:25-32.
123. Sengupta J.N., Snider A., Su X., Gebhart G.F. Effects of kappa opioids in the inflamed rat colon. Pain 1999, 79:175-185.
124. Binder W., Machelska H., Mousa S., Schmitt T., Riviere P.J., Junien J.L., Stein C., Schafer M. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology 2001, 94:1034-1044.
125. Furst S., Riba P., Friedmann T., Timar J., Al-Khrasani M., Obara I., Makuch W., Spetea M., Schutz J., Przewlocki R., Przewlocka B., Schmidhammer H. Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J. Pharmacol. Exp. Ther. 2005, 312:609-618.
126. Nunez S., Lee J.S., Zhang Y., Bai G., Ro J.Y. Role of peripheral mu-opioid receptors in inflammatory orofacial muscle pain. Neuroscience 2007, 146:1346-1354.
127. Ji R.R., Zhang Q., Law P.Y., Low H.H., Elde R., Hokfelt T. Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J. Neurosci. 1995, 15:8156-8166.
128. Puehler W., Zollner C., Brack A., Shaqura M.A., Krause H., Schafer M., Stein C. Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neuroscience 2004, 129:473-479.
129. Zöllner C., Shaqura M.A., Bopaiah C.P., Mousa S., Stein C., Schafer M. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol. Pharmacol. 2003, 64:202-210.
130. McDougall J.J., Barin A.K., McDougall C.M. Loss of vasomotor responsiveness to the μ-opioid receptor ligand endomorphin-1 in adjuvant monoarthritic rat knee joints. Am. J. Physiol. Reg. Integr. Comp. Physiol. 2004, 286:R634-R641.
131. Mousa S.A., Machelska H., Schafer M., Stein C. Immunohistochemical localization of endomorphin-1 and endomorphin-2 in immune cells and spinal cord in a model of inflammatory pain. J. Neuroimmunol. 2002, 126:5-15.
132. Li Z., Proud D., Zhang C., Wiehler S., McDougall J.J. Chronic arthritis downregulates peripheral mu-opioid receptor expression with concomitant loss of endomorphin-1 anti-nociception. Arthritis Rheum. 2005, 52:3210-3219.
133. Rosseland L.A., Stubhaug A., Grevbo F., Reikeras O., Breivik H. Effective pain relief from intra-articular saline with or without morphine 2mg in patients with moderate-to-severe pain after knee arthroscopy: a randomized, double-blind controlled clinical study. Acta Anaesthesiol. Scand. 2003, 47:732-738.
134. Ruwe P.A., Klein I., Shields C.L. The effect of intraarticular injection of morphine and bupivacaine on postarthroscopic pain control. Am. J. Sports Med. 1995, 23:59-64.
135. Wrench I.J., Taylor P., Hobbs G.J. Lack of efficacy of intra-articular opioids for analgesia after day-case arthroscopy. Anaesthesia 1996, 51:920-922.